Eurofins Central Laboratory, headquartered in Lancaster, Pennsylvania and a member of Eurofins Scientific, a global leader in testing and laboratory services, joined the COVID-19 Pennsylvania testing program after State Health Secretary Dr. Rachel Levine ordered the testing of nursing home residents and staff in the state.

Eurofins Lancaster site was founded in 1961 and has become an industry leader and Pennsylvania flagship known for innovative business practices and people-friendly policies, and now provides clinical, environmental, pharmaceutical, biopharmaceutical, food and professional scientific services to customers worldwide. The company has benefited from Commonwealth support for multiple expansions over the years, and today operates on a 500,000-square-foot campus, providing jobs to over 2,000 Pennsylvania citizens. More broadly, Eurofins employs over 3,000 Pennsylvanians across the state.

From the onset of the COVID-19 crisis, Eurofins mobilized all available scientific talent and resources from its over 800 global testing sites to help its clients and the world fight the pandemic. Eurofins offers its clients (both in the private industry and government sectors) an extensive capacity for quick turnaround time COVID-19 clinical testing, as well as a full complement of solutions through our SAFER@WORK™ program.

This includes consultation services (designing testing protocols, testing frequency on risk based modelling, site selection, corrective action plans), sentinel testing (air and wastewater COVID-19 testing, surface testing), employee, student, staff and resident testing (through RT-PCR and serological methods), product testing (masks, gloves, gowns, respiratory devices, disinfectants, sanitizers) and using the latest technology for ancillary services (electronic employee/resident screening, consent, symptom tracking; Bluetooth contact tracing solutions; authorized medical authority ordering services, and qualified health provider specimen collection services).

Globally there are more than 3,000 clinical trials in vaccines, treatments and diagnostics for COVID-19 in development, and Eurofins is the go-to partner in support of analytical testing solutions. Eurofins extensive capacity for RT-PCR viral testing is used to diagnose active infection; and available Antibody IgG and IgM testing can help identify antibody response to the virus after infection. Additionally, antibody testing can identify people that were exposed to the virus and may have developed some level of immunity, but experienced only mild to no symptoms.

To learn more about Eurofins SAFER@WORK™ employee/faculty/resident testing, please visit: https://www.eurofins.com/covid-19-response/safer-work/

To learn more about Eurofins Central Laboratory COVID-19 clinical trial testing, please visit: https://eurofinscentrallaboratory.com/covid-19/

For more information, please visit www.eurofins.com or contact:

Investor Relations Eurofins Scientific SE Phone: +32-2-766 1620 E-mail: ir@eurofins.com

Notes for the editor:

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.